Eli Lilly (LLY)
1,105.00
+1104.89 (981249.91%)
NYSE· Last Trade: May 30th, 12:21 PM EDT
Detailed Quote
| Previous Close | 0.1126 |
|---|---|
| Open | 0.1127 |
| Bid | 1,102.25 |
| Ask | 1,108.00 |
| Day's Range | 1,089.01 - 1,132.66 |
| 52 Week Range | 623.78 - 1,149.10 |
| Volume | 4,603,032 |
| Market Cap | 1.06T |
| PE Ratio (TTM) | 48.15 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.63%) |
| 1 Month Average Volume | 3,567,275 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
ASML's lithography machines are needed to manufacture advanced AI processing and memory chips.
Via The Motley Fool · May 30, 2026
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.
Via The Motley Fool · May 30, 2026
Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.
Via The Motley Fool · May 30, 2026

Lilly has split its stock in the past.
Via The Motley Fool · May 30, 2026
Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.
Via The Motley Fool · May 28, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferre...
Via StockStory · May 28, 2026
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.
Via The Motley Fool · May 28, 2026

Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo.
Via Benzinga · May 28, 2026
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.
Via MarketBeat · May 28, 2026
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.
Via The Motley Fool · May 28, 2026
Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.
Via Barchart.com · May 28, 2026
Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.
Via Barchart.com · May 28, 2026
Buying and holding stocks is an excellent strategy to increase your wealth.
Via The Motley Fool · May 28, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...
Via StockStory · May 28, 2026
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less roo...
Via StockStory · May 28, 2026
There is no reason to panic just yet.
Via The Motley Fool · May 27, 2026
Eli Lilly's fundamentals matter more than Trump's stock purchases.
Via The Motley Fool · May 27, 2026
Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.
Via Barchart.com · May 27, 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
Via The Motley Fool · May 27, 2026
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.
Via The Motley Fool · May 27, 2026
Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk.
Via The Motley Fool · May 26, 2026
Consumer demand for Eli Lilly's weight-loss treatments continues to rise.
Via The Motley Fool · May 26, 2026
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
Via The Motley Fool · May 26, 2026
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.
Via Benzinga · May 26, 2026
For some types of restaurants, the damage is bigger.
Via Investor's Business Daily · May 26, 2026